A review found emerging but insufficient evidence for cannabinoids in treating rheumatic diseases
A Nature Reviews Rheumatology article reviewed preliminary clinical trials on cannabis for rheumatoid arthritis, osteoarthritis, and fibromyalgia, concluding that while cannabinoids show immunomodulatory potential, evidence is not yet sufficient to recommend them for rheumatic diseases.
Quick Facts
What This Study Found
Researchers reviewed the available evidence on cannabinoids for rheumatic diseases.
Preliminary clinical trials have explored cannabis effects on rheumatoid arthritis, osteoarthritis, and fibromyalgia. Additional preclinical evidence links the cannabinoid system to systemic sclerosis and juvenile idiopathic arthritis.
Cannabinoids exert immunomodulatory effects on multiple immune cell types including T cells, B cells, and macrophages, which is theoretically relevant to autoimmune rheumatic conditions.
Pain is considered a prevalent indication for medicinal cannabis in countries where it is legal, and rheumatic disease pain is a common reason patients seek cannabis.
However, the authors concluded that available evidence is not sufficient to support recommending cannabinoid treatment for rheumatic diseases, calling for more rigorous research.
Key Numbers
Preliminary trials covered rheumatoid arthritis, osteoarthritis, and fibromyalgia. Immunomodulatory effects documented on T cells, B cells, and macrophages. Associations noted with systemic sclerosis and juvenile idiopathic arthritis.
How They Did This
Narrative review published in Nature Reviews Rheumatology covering clinical trials, preclinical studies, and immunological research on cannabinoids in rheumatic disease contexts.
Why This Research Matters
Rheumatic disease patients are among the most common users of medical cannabis for pain, yet rheumatologists have limited evidence to guide them. This high-profile review from a top rheumatology journal summarizes what is and is not known.
The Bigger Picture
The gap between patient demand for cannabis-based rheumatic disease treatment and the available evidence base is a recurring theme in medical cannabis research. Patients are using cannabis for these conditions regardless of whether sufficient evidence exists.
What This Study Doesn't Tell Us
Narrative review rather than systematic review. Available primary studies are small, few, and methodologically limited. The authors acknowledge that evidence is insufficient for clinical recommendations.
Questions This Raises
- ?Which specific cannabinoids and formulations would be most appropriate for different rheumatic conditions?
- ?Can cannabinoid immunomodulation be harnessed without psychoactive side effects?
- ?Do topical cannabinoid applications work for localized joint pain?
Trust & Context
- Key Stat:
- Evidence is not yet sufficient to recommend cannabinoids for rheumatic diseases
- Evidence Grade:
- Moderate. Published in a top specialty journal with thorough coverage, but reflects the preliminary state of the underlying evidence.
- Study Age:
- Published in 2018 in Nature Reviews Rheumatology. Research on cannabinoids for inflammatory and autoimmune conditions has continued to develop.
- Original Title:
- Cannabinoids for the treatment of rheumatic diseases - where do we stand?
- Published In:
- Nature reviews. Rheumatology, 14(8), 488-498 (2018)
- Database ID:
- RTHC-01715
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Can cannabis help with arthritis pain?
Some patients report pain relief from cannabis, and preliminary trials have explored this. However, as of this 2018 review, the evidence was not strong enough for rheumatologists to formally recommend cannabis for arthritis. The immunomodulatory properties of cannabinoids are theoretically promising but need more rigorous study.
How do cannabinoids affect the immune system?
Cannabinoids interact with CB1 and CB2 receptors found on immune cells including T cells, B cells, and macrophages. This can modulate inflammatory responses, which is relevant to autoimmune conditions like rheumatoid arthritis. However, the clinical significance of these effects in treating disease is not yet established.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- cannabis-and-arthritis-research
Cite This Study
https://rethinkthc.com/research/RTHC-01715APA
Katz-Talmor, Daphna; Katz, Itay; Porat-Katz, Bat-Sheva; Shoenfeld, Yehuda. (2018). Cannabinoids for the treatment of rheumatic diseases - where do we stand?. Nature reviews. Rheumatology, 14(8), 488-498. https://doi.org/10.1038/s41584-018-0025-5
MLA
Katz-Talmor, Daphna, et al. "Cannabinoids for the treatment of rheumatic diseases - where do we stand?." Nature reviews. Rheumatology, 2018. https://doi.org/10.1038/s41584-018-0025-5
RethinkTHC
RethinkTHC Research Database. "Cannabinoids for the treatment of rheumatic diseases - where..." RTHC-01715. Retrieved from https://rethinkthc.com/research/katz-talmor-2018-cannabinoids-for-the-treatment
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.